Another study [11] found that JWH-015, a CB2 agonist, could inhibit EGFR (Epidermal growth factor receptor), FAK (Focal adhesion kinase), VCAM1 (Vascular cell adhesion protein 1), and MMP2 (Matrix metallopeptidases2) pathways and prevent the accumulation of tumor-associated macrophages (TAMs) and control NSCLC lung cancer cells invasion. Here, EGFR is linked to non-small cell lung carcinoma.